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ABSTRACT
AIM: Historically methoxyflurane was used for anaesthesia. Evidence of nephrotoxicity led to 
abandonment of this application. Subsequently, methoxyflurane, in lower doses, has re-emerged as 
an analgesic agent, typically used via the Penthrox inhaler in the ambulance setting. We review the 
literature to consider patient and occupational risks for methoxyflurane.
METHOD: Articles were located via PubMed, ScienceDirect, Google Scholar, Anesthesiology journal and 
the Cochrane Library.
RESULTS: Early studies investigated pharmacokinetics and considered the resulting effects to 
pose minimal risk. Pre-clinical rodent studies utilised a species not vulnerable to the nephrotoxic 
fluoride metabolite of methoxyflurane, so nephrotoxicity was not identified until almost a decade 
after its introduction, and was initially met with scepticism. Further evidence of nephrotoxicity led 
to abandonment of methoxyflurane use for anaesthesia. Subsequent research suggested there are 
additional risks potentially relevant to recurrent patient or occupational exposure. Specifically, greater 
than expected fluoride production after repeated low-dose exposure, increased fluoride production 
due to medication-caused hepatic enzyme induction, fluoride deposition in bone potentially acting as 
a slow-release fluoride compartment, which suggests a risk of skeletal fluorosis, and hepatotoxicity. 
Gestational risk is unclear.
CONCLUSIONS: Methoxyflurane poses a potentially substantial health risk in high (anaesthetic) doses, 
and there are a number of pathways whereby repeated exposure to methoxyflurane in lower doses 
may pose a risk. Single analgesic doses in modern use generally appear safe for patients. However, the 
safety of recurrent patient or occupational healthcare-worker exposure has not been confirmed, and 
merits further investigation.
Methoxyflurane is a volatile organic liquid,1 a fluorinated hydrocarbon, that vaporises readily2 and has 
historically been used as an anaesthetic 
agent from 1958.3 A decade after discovery, 
methoxyflurane was used frequently, mak-
ing up 10% of annual purchases of inhaled 
anaesthetics in the USA.3 Sedative and 
analgesic effects were described,4,5 which 
prompted an extension of its use outside 
of the operating room for indications such 
as labour pain6–8 and dressing changes.9 
Renal failure was identified in some patients 
anaesthetised with methoxyflurane.10,11 
Methoxyflurane is estimated to have been 
responsible for clinical nephrotoxicity in 
approximately 100 patients worldwide, and 
death in approximately 20 cases, before its 
near universal discontinuation since the 
1970s.12
However, methoxyflurane has been 
reintroduced into the contemporary arma-
mentarium as an analgesic for emergency or 
short procedures. Australasia,13,14 Europe,15 
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Canada,16 South Africa17 and, more recently, 
numerous other countries18 allow methoxy-
flurane administration via the Penthrox 
inhaler. This device has been manufactured 
by Medical Developments International 
(formerly Medical Developments Australia) 
since 1978, specifically for analgesic use,19 
and Penthrox is currently the only widely 
commercially available methoxyflurane 
administration device. The Penthrox inhaler 
is a tube into which the methoxyflurane 
medication is poured to soak a wick, with a 
whistle-like mouthpiece through which the 
patient inhales methoxyflurane vapour.20 
The device features a ‘dilution hole’, which 
allows the patient to control the concen-
tration delivered18,21 and can incorporate 
an activated carbon (AC) filter through 
which the patient is encouraged to exhale. 
Methoxyflurane has an estimated atmo-
spheric lifetime of 54 days and a 100-year 
global warming potential four times that 
of carbon dioxide, although it compares 
favourably in that regard against other 
inhalational anaesthetics.22 Administration 
of methoxyflurane via the Penthrox inhaler 
has been demonstrated as more effective at 
relieving pain than placebos and alternative 
analgesia in a variety of settings including 
pre-hospital,23,24 clinic,25 and emergency 
department.26,27
We reviewed the historic literature to 
describe the evolution in the understanding 
of the health risks associated with anaes-
thetic methoxyflurane. Thus we identify 
the potential patient and occupational risks 
of methoxyflurane in the modern setting, 
in order to help guide policymakers and 
clinicians who might consider making 
methoxyflurane available in their clinical 
environments.
Search strategy
To gain a comprehensive overview of the 
historical literature, we sought to locate 
research and commentary on methoxy-
flurane administration in any setting for 
any indication by any method other than 
the modern Penthrox inhaler. Articles were 
located using PubMed, ScienceDirect and 
Google Scholar and by searching the Anes-
thesiology journal and Cochrane Library 
databases with the term ‘methoxyflurane’. 
Articles were selected based on rele-
vance to health effects, as categorised in 
the following sections of this paper. Only 
English-language material was reviewed. 
Reference sections of relevant articles 
were examined to identify further relevant 
material for inclusion. Documents included 
in this review range across case reports, 
animal and human prospective observa-
tional studies, experimental trials and other 
literature reviews.
Historic use of 
methoxyflurane
Early published animal studies were 
conducted on dogs and determined 
that, with regards to incidence of lethal 
arrhythmias,29,30 electrolyte disturbances 
or liver dysfunction,31 methoxyflurane 
compared favourably with alternative 
inhaled anaesthetic agents. Reports were 
conflicted with regards to cardiovascular 
and respiratory effects,31–33 although these 
risks are not generally discussed in later 
investigations. Researchers of canine 
models noted a slow recovery from anaes-
thesia, with the dogs appearing sluggish 
until the next day.31 Anaesthetised human 
subjects also exhibited slow onset and 
emergence from anaesthesia.4 Arterial 
methoxyflurane was approximately double 
the venous level during early anaesthesia 
(2 to 15 minutes), equilibrating after 100 
minutes.34 This suggests ready uptake into 
tissue, confirming laboratory studies that 
had suggested methoxyflurane would have 
high solubility in blood and high uptake in 
adipose tissue.28 Methoxyflurane concen-
tration in subcutaneous fat rose slowly, 
peaking 5–8 hours after commencement 
of anaesthesia and remaining elevated 
beyond 30 hours after cessation.34 Overall, 
these studies suggested that methoxyflurane 
had a large volume of distribution and 
consequent delayed equilibration between 
compartments.
As methoxyflurane was a new anaes-
thetic agent, a significant proportion of the 
historical animal and human research was 
dedicated to investigating the rate of onset 
of and emergence from anaesthesia,4,31,35,36 
the concentration required to achieve 
adequate anaesthesia1,20,37 and the threshold 
of sedation.36 Early medication safety investi-
gations included effects on respiration2,4,31,35,38 
and cardiovascular stability,4,35,38,39 with 
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methoxyflurane demonstrating reasonable 
safety with regards to these concerns. 
Although many of these historical anaes-
thesia studies might not meet modern 
scientific standards due to the poor quality 
and quantity of data, examination of this 
literature nonetheless allows identification 
and extraction of worthwhile findings.
Fluoride-associated health effects
Methoxyflurane is metabolised by lung 
and liver tissue into a variety of products,40 
including fluoride and oxalic acid.20 
Some medications are known to increase 
(‘induce’) metabolism pathways in the liver. 
Pre-treatment of rat hepatic microsomes 
in vitro with phenobarbital, an anticon-
vulsant therapy,41 caused a 7- to 10-fold 
increase in fluoride production in response 
to methoxyflurane exposure.40,42 Similarly, 
in vivo pre-treatment of rats with pheno-
barbital increased methoxyflurane uptake 
and fluoride production.43–45 A patient 
who had secobarbital prior to receiving 
methoxyflurane had peak serum fluoride 
that was three times that of patients who 
did not receive secobarbital, and the patient 
subsequently exhibited a decrease in renal 
function. This suggests increased risk of 
elevated serum fluoride, and possibly 
increased susceptibility to health effects 
associated with elevated fluoride levels, for 
exposed individuals concomitantly using 
medications that affect methoxyflurane 
metabolism.
Prolonged exposure to methoxyflurane 
also causes enzyme induction, altering 
methoxyflurane metabolism.46 Rat hepatic 
microsomes in vitro exposed to low-dose 
methoxyflurane produced proportionally 
more fluoride than with high-dose 
exposure,42 and the susceptible Fischer 344 
rat strain demonstrated prolonged low-dose 
exposure also resulting in increased fluoride 
production.47 This nonlinear response 
suggests extrapolation from single high-dose 
outcomes to repeated low-dose use or occu-
pational exposure 48–50 cannot be undertaken 
with simple linear assumptions.
Renal toxicity
Although preclinical trials conducted in 
Sprague-Dawley rats found no evidence of 
nephrotoxicity,51 over a decade later it was 
determined that different rat types exhibited 
different degrees of hepatic conversion 
of methoxyflurane into fluoride. Only 
Fischer 344 rats demonstrated biochemical 
and pathological renal changes following 
methoxyflurane anaesthesia.51 In susceptible 
rats, elevated fluoride was associated with 
dose-related high-output renal failure.43,52,53 
Therefore, due to the use of a non-sus-
ceptible rat type, preclinical trials had 
unfortunately failed to identify the nephro-
toxic potential of methoxyflurane.
Early observations of anaesthetised 
human subjects also suggested no renal 
toxicity.35 Nephrotoxicity in clinical use 
was suggested by a 1966 case series of 17 
patients,10 although unfortunately this first 
report of human methoxyflurane anaes-
thesia-associated nephrotoxicity was met 
with scepticism.12 It was a further five 
years until further incidents of high-output 
failure were described,54–56 at which time a 
relationship was identified between serum 
fluoride following methoxyflurane anaes-
thesia and the degree of renal toxicity. In 
1973, strong correlations were identified 
between methoxyflurane anaesthetic dose, 
increased serum inorganic fluoride concen-
tration and the degree of nephrotoxicity,11 
with further biochemical evidence of renal 
dysfunction emerging the following year 
from patients receiving methoxyflurane 
anaesthesia.39,60 Two types of methoxy-
flurane-induced renal pathology were 
identified: low output failure exhibited 
calcium oxalate crystals in the tubules of 
the renal cortex and the collecting tubules 
of the medulla, with cortex tubular inflam-
matory changes;61 whereas high output 
failure exhibited tubular necrosis,51 wide-
spread tubular dilatation and calcium and 
calcium oxalate crystals in the tubular 
epithelium.62 In combination, these 
findings provided “compelling scientific 
evidence [which] led practitioners and 
the manufacturer to abandon methoxy-
flurane.”12 Methoxyflurane administration 
to human patients for both anaesthesia 
and analgesia was generally discontinued 
around 1974.19,63 
There appears to be inter-person variation 
in response to serum fluoride resulting from 
methoxyflurane, with some studies demon-
strating serum fluoride levels above the 
toxic threshold11 without identifying renal 
dysfunction.65,66 This variability may be 
partially explained by additive nephrotox-
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icity from medications, such as tetracycline 
or other antibiotics,67,68 that can alter typical 
methoxyflurane dose-responses, although 
variable susceptibility to the effects of 
fluoride and/or other metabolites is also a 
possibility. 
Interestingly, the renal toxic serum 
fluoride threshold is not necessarily 
consistent across fluorinated anaesthetic 
agents.71–73 For example, sevoflurane, which 
undergoes minimal renal defluorination 
compared with methoxyflurane, some-
times produces serum fluoride ≥50µmol/L 
without apparent renal dysfunction.71 
Transient changes in renal function have 
been observed in some studies using rats 
and human subjects following sevoflurane 
anaesthesia. The renal changes are believed 
to be due to a different compound that is 
formed by sevoflurane and unrelated to 
fluoride formation.74 However, differences 
in renal function following sevoflurane 
are not statistically significant on meta-
analysis.75 It has been suggested that 
the more pronounced renal metabolism 
exhibited by methoxyflurane is responsible 
for its comparatively greater renal toxic 
effect.70,71 Direct comparison between agents 
is challenging.
Fluoride bone deposition
A 1973 study of mice and Wistar rats 
found 4.7–6.7% of the fluoride in methoxy-
flurane was deposited in bone. Washout 
of bone fluoride was slow, returning to 
control after 40–60 days. In concert with the 
findings of enzyme induction studies,40,42 
phenobarbital increased the amount of 
fluoride deposited in bone.77 Subsequent 
research confirmed fluoride deposition in 
rat bone following methoxyflurane anaes-
thesia, with preferential deposition in foetal 
bone in the third trimester of pregnancy.78 
Similarly, recurrent high-dose exposure 
appears to cause decreased foetal ossifi-
cation and minor skeletal abnormalities in 
mice.79
These findings suggest that bone has the 
potential to act as a long-acting storage 
compartment of fluoride metabolite, which 
raises the possibility of fluoride accumu-
lation with repeated exposure within an 
extended clearance time frame. Elevated 
fluoride intake is associated with both 
elevated serum fluoride and increased 
skeletal fluorosis risk,80,81 suggesting the 
potential for skeletal fluorosis in exposed 
persons or the foetuses of exposed pregnant 
persons. However, the quantity of risk is 
unclear in the context of modern analgesic 
use and occupational exposure, and further 
study is needed.
Gestational effects
In rats, recurrent subanaesthetic methoxy-
flurane exposure does not appear to 
significantly alter foetal loss, but it does 
decrease foetal weight.82 In mice, recurrent 
low-dose exposure to methoxyflurane 
provokes increased rates of foetal devel-
opment variation, and frequent higher-dose 
(though still subanaesthetic) exposure 
causes decreased birth weight and increased 
rates of death in utero.79 These findings 
suggest that there are potentially gestational 
effects consequent of recurrent maternal 
exposure, although large human cohort 
studies are needed to examine whether such 
effects occur with modern use.
Women in labour receiving methoxy-
flurane analgesia during labour produce 
fluoride that appears in their urine and 
the urine of their newborns.83,84 The 
biological effect of maternal methoxy-
flurane analgesia on newborns has not 
been studied in humans. Likewise, human 
antenatal methoxyflurane use does not 
appear to have been explicitly studied.85 
Furthermore, there appears to be an 
absence of research of the occupational 
safety of pregnant healthcare workers 
exposed to methoxyflurane.
Hepatotoxicity
Researchers in 1962 noted no clinical 
indications of liver toxicity in two patient 
cohorts anaesthetised with methoxy-
flurane.35,38 However, subsequent case 
reports of hepatitis emerged, which were 
associated with anaesthesia,86 delivery7,8 
and medication abuse.87 The majority 
of these reports occurred as or after 
methoxyflurane was becoming used less 
frequently worldwide. A further study in 
1980 identified changes in hepatic function 
biomarkers following occupational exposure 
of delivery-ward personnel.88 Hepatotox-
icity appears to have been an infrequent 
but important effect that was unpredictably 
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Summary of historical use
In the 1960s, methoxyflurane was a new 
anaesthetic agent. Research focused on 
determining its pharmacokinetics, utility 
as an anaesthetic agent, respiratory effects 
and cardiovascular changes. None of these 
factors were ultimately determined to be 
areas of significant risk. Methoxyflurane 
appeared to be a useful agent for providing 
stable anaesthesia with gradual emergence.
Nephrotoxicity was only identified after 
approximately a decade of use and was not 
formally associated as a methoxyflurane 
dose-response until approximately 15 years 
after its introduction. Individual variation 
in nephrotoxic threshold added further 
complication, and it is possible scepticism 
may have impeded research into toxic 
effects. Hepatotoxicity occurred infre-
quently enough that it was not identified as 
an important risk of methoxyflurane, and 
the combination of circumstances under 
which methoxyflurane causes hepatitis are 
still unclear.
Studies of hepatic induction of methoxy-
flurane metabolism suggest that frequent 
low-dose uses or exposures, or some medica-
tions taken concomitantly, have the potential 
to produce proportionally greater toxicity 
than historical one-off high dose exposures. 
Bone fluoride deposition as a result of 
methoxyflurane exposure has been mini-
mally studied. A small but not irrelevant 
teratogenic risk is suggested by two animal 
studies undertaken after methoxyflurane 
use had generally ceased.
Relevance to the 
modern setting
This review was undertaken with the goal 
of including the widest possible range of 
historical literature in order to describe the 
evolution of understanding of the health 
risks associated with methoxyflurane. 
Literature was located non-systematically, 
including extensive use of locating citations 
and a wide range of search terms. Thus, the 
review search is not completely systematic, 
but it is nonetheless comprehensive. Equally, 
due to near-global abandonment of studies 
in the 1970s, research was restricted until 
recently, which limits numbers and avail-
ability of prior publications. Much of the 
historical data utilise small samples and lack 
a control group, but nonetheless it is highly 
unlikely that anaesthetic methoxyflurane 
studies will ever be repeated to ensure 
scientific rigour.
Methoxyflurane is experiencing a revival 
in lower-dose analgesic use. The historical 
experience has provided some insight into 
risk in the modern setting, with researchers 
specifically investigating the possibility and 
finding no evidence of patient nephrotox-
icity and hepatotoxicity in current use.27,89 
However, the literature suggests some unre-
solved safety concerns.
The Australian Therapeutic Goods Admin-
istration (TGA) reported 25 cases of adverse 
reaction associated with Penthrox between 
1971 and 19 July 2020. These cases included 
two deaths and one report of adverse effect 
due to occupational exposure.90 The New 
Zealand Medicines and Medical Devices 
Safety Authority (Medsafe) reported six 
cases of adverse reaction associated with 
Penthrox between 2000 and 19 October 
2020, with no deaths.91 These reports are 
aggregated in Table 1. The earliest report in 
the Australian TGA database is November 
2005, and the earliest report in the New 
Zealand Medsafe database is January 2012. 
Hence it is possible that any earlier events 
were unreported.90,91 It is important to 
acknowledge that association with adverse 
events does not necessarily imply methoxy-
flurane caused the event. However, these 
reports suggest a non-zero risk requiring 
surveillance and investigation.
In contemporary use in Australasia, 
patients are administered up to 6mL 
methoxyflurane per day and up to 15mL per 
week.13,14 Each 3mL dose lasts between 20 
and 60 minutes depending on how intensely 
the patient inhales.92 Methoxyflurane is used 
by Australian and New Zealand ambulance 
services,23,24,48,89,92–99 by at least one Australian 
emergency department100 and in Austral-
asian in-hospital and clinic settings.25,101–108 
It has been administered to five million 
patients in Australia18 and a further one 
million patients outside of Australia.112 Given 
this extensive use, the number of adverse 
events reported is reassuringly low, and 
suggests that modern use of methoxyflurane 
may be safe for short-term administration. 
Furthermore, the low rate of adverse effects 
implies relative safety for those who are 
occupationally exposed to methoxyflurane. 
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Table 1: Aggregated reports of adverse events involving methoxyflurane from the Australian Therapeutic Goods Administration 
(TGA)90 and the New Zealand Medicines and Medical Devices Safety Authority (Medsafe).91
























Nov 2005 Australia Male 57 Hypoxia, medi-
cation error
None reported None reported
Dec 2005 Australia Female 34 Confusion, diz-
ziness, hypoxia, 
somnolence
None reported None reported




None reported None reported
Mar 2008 Australia Male 26 Blood pressure 
fluctuation
None reported None reported








Feb 2010 Australia Female Not reported Hepatic failure, 
renal failure
None reported None reported
Jul 2010 Australia Male 19 Affect lability, 
amnesia
None reported None reported














Jan 2012 New Zealand Male 64 Hepatic failure None reported None reported
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Apr 2015 Australia Female Not reported Liver function 
test increased
None reported None reported




None reported None reported




None reported None reported






Sep 2017 New Zealand Male 36 Dizziness, mal-
aise, nausea
None reported None reported





None reported None reported
Aug 2018 Australia Male Not reported Depressed level 
of conscious-
ness
None reported None reported
Aug 2018 New Zealand Male 11 Abnormal 
behaviour, de-






Oct 2018 Australia Male Not reported Drug abuse, 
hepatitis
None reported None reported




None reported Not reported
May 2019 Australia Female 48 Aggression, 
amnesia
None reported None reported
Table 1: Aggregated reports of adverse events involving methoxyflurane from the Australian Therapeutic Goods Administration 
(TGA)90 and the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) (continued).91
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None reported None reported
Jul 2019 Australia Female Not reported Intentional 
product misuse
None reported None reported
Aug 2019 Australia Female 75 Aphasia None reported None reported





Sep 2019 Australia Male Not reported Nephropathy None reported None reported











Table 1: Aggregated reports of adverse events involving methoxyflurane from the Australian Therapeutic Goods Administration 
(TGA)90 and the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) (continued).91
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However, absence of evidence does not 
necessarily mean an absence of harm, and it 
may be difficult to identify the true risk. The 
identification of potential nephrotoxic and 
other risks, combined with the low numbers 
and high age of prior studies, provides 
a basis for consideration of research of 
methoxyflurane safety in the modern 
setting. The literature illustrates a paucity 
of clinical trials confirming the safety of 
methoxyflurane in cases other than one-off 
analgesic administration. Therefore, despite 
the apparent relative safety in modern use 
thus far, there is good cause for further 
research to be undertaken to ensure the 
safety of patients and healthcare workers.
In summary, the risks of patient and 
occupational methoxyflurane exposure 
have been identified. The degree of risk for 
patients and healthcare workers appears 
low, but nonetheless remains unquantified 
in the following domains: 
• renal toxicity
• enzyme induction due to concomitant 
medication use or repeated methoxy-
flurane exposure
• a possibility of fluoride bone depo-
sition with unknown skeletal fluorosis 
risk
• hepatotoxicity.
Additionally, there is a notable dearth of 
research of gestational effects relating to 
repeated methoxyflurane exposure. Because 
of these currently unquantified risks, it 
may be prudent for healthcare workers 
to minimise exposure through adequate 
environment ventilation and by directing 
patients to exhale through the AC filter of 
the Penthrox device.
A number of areas for future research 
are suggested. For example, prolonged 
compartmental equilibration28,34 suggests a 
potential for healthcare workers to accu-
mulate methoxyflurane and metabolites 
with repeated exposure over prolonged 
periods. Whether such an effect occurs 
has been investigated only by one pilot 
study,113 and further research is warranted. 
The rate of use among both patients and 
healthcare workers of relevant enzyme-in-
ducing and nephrotoxic medications could 
be considered in the context of the increased 
risk posed by concomitant methoxyflurane 
use or exposure. Skeletal fluorosis, gesta-
tional and hepatotoxic risk should be 
further investigated. Workplaces where 
methoxyflurane vapour is present could 
institute monitoring of at-risk healthcare 
workers’ urine fluoride against published 
guidelines114,115 as a general health measure. 
Although the historical literature associates 
serum fluoride level with renal toxicity, Safe 
Work Australia does not recommend work-
places institute serum fluoride testing, due 
to practical complexities.115
Although there has been some 
primary108,116 and secondary48 reporting 
of occupational exposure ranges with the 
Penthrox inhaler, the degree to which 
patients exhale methoxyflurane into the 
local environment beyond the duration of 
their treatment could be explained further 
as this might cause exposure for other 
healthcare workers who subsequently 
receive and care for the patient. A recent 
study supported by the Penthrox manu-
facturer derived an eight-hour Maximum 
Exposure Limit by estimating the level 
at which there is a 10% increased risk of 
kidney toxicity from historical single-ex-
posure anaesthetic data.48 This provides a 
useful measure against which to compare 
reported or predicted exposures. However, 
independent confirmation of this Maximum 
Exposure Limit would be ideal.48,117,118 
Finally, the only recently published deter-
minations of occupational health risk have 
been theoretical models and extrapolation to 
compare with a single-exposure nephrotoxic 
threshold.48–50 Further research to determine 
the nephrotoxic and other health effect risk 
associated with recurrent exposure would 
be valuable. The historical literature has 
been examined and the evolution of under-
standing of health risks associated with 
methoxyflurane described. This stands as a 
case study of a medication enthusiastically 
put into clinical practice without sufficient 
confirmation of occupational safety. Policy-
makers should take heed of the persistent 
need for scientific confirmation of the 
occupational safety of methoxyflurane 
administration, and also of the potential for 
similar oversights that could occur with the 
utilisation of new medications or medica-
tions with controversial characteristics.
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